Skyrmionic textures in chiral magnets

In non-centrosymmetric magnets the chiral Dzyaloshinskii-Moriya exchange stabilizes Skyrmion-strings as excitations which may condense into multiply modulated phases. Such extended Skyrmionic textures are determined by the stability of the localized "solitonic" Skyrmion cores and their geometrical incompatibility which frustrates regular space-filling. We present numerically exact solutions for Skyrmion lattices and formulate basic properties of the Skyrmionic states.Comment: Conference information: The International Conference on Magnetism (ICM), Karlsruhe, July 26 - 31, 200

Chiral Skyrmionic matter in non-centrosymmetric magnets

Axisymmetric magnetic strings with a fixed sense of rotation and nanometer sizes (chiral magnetic vortices or Skyrmions) have been predicted to exist in a large group of non-centrosymmetric crystals more than two decades ago. Recently these extraordinary magnetic states have been directly observed in thin layers of cubic helimagnet (Fe,Co)Si. In this report we apply our earlier theoretical findings to review main properties of chiral Skyrmions, to elucidate their physical nature, and to analyse these recent experimental results on magnetic-field-driven evolution of Skyrmions and helicoids in chiral helimagnets.Comment: 13 pages, 7 figures, invited talk - JEMS-2010 ( 23-28 August, Krakow, Poland

Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression

Parkinson's disease (PD) represents an increasing problem in society. The oligomerization of alpha-synuclein (alpha Syn) is a suggested key event in its pathogenesis, yet the pathological modes of action remain to be fully elucidated. To identify potential disease-modifying therapeutics and to study alpha Syn-mediated toxic mechanisms, we established cell lines with inducible overexpression of different alpha Syn constructs: alpha Syn, alpha Syn coupled to the fluorescence protein Venus (alpha Syn-Venus), and alpha Syn coupled to the N-terminal or C-terminal part of Venus (V1S and SV2, respectively) for a bimolecular fluorescence complementation assay (BiFC). Inducibility was achieved by applying modified GAL4-UAS or Cre-loxP systems and addition of tebufenozide or 4-OH-tamoxifen, respectively. Expression constructs were stably integrated into the host genome of H4 neuroglioma cells by lentiviral transduction. We here demonstrate a detailed investigation of the expression characteristics of inducible H4 cells showing low background expression and high inducibility. We observed increased protein load and aggregation of alpha Syn upon incubation with DMSO and FeCl3 along with an increase in cytotoxicity. In summary, we present a system for the creation of inducibly alpha Syn-overexpressing cell lines holding high potential for the screening for modulators of alpha Syn aggregation and alpha Syn-mediated toxicity

Function of the ribosomal E-site: a mutagenesis study

Ribosomes synthesize proteins according to the information encoded in mRNA. During this process, both the incoming amino acid and the nascent peptide are bound to tRNA molecules. Three binding sites for tRNA in the ribosome are known: the A-site for aminoacyl-tRNA, the P-site for peptidyl-tRNA and the E-site for the deacylated tRNA leaving the ribosome. Here, we present a study of Escherichia coli ribosomes with the E-site binding destabilized by mutation C2394G of the 23S rRNA. Expression of the mutant 23S rRNA in vivo caused increased frameshifting and stop codon readthrough. The progression of these ribosomes through the ribosomal elongation cycle in vitro reveals ejection of deacylated tRNA during the translocation step or shortly after. E-site compromised ribosomes can undergo translocation, although in some cases it is less efficient and results in a frameshift. The mutation affects formation of the P/E hybrid site and leads to a loss of stimulation of the multiple turnover GTPase activity of EF-G by deacylated tRNA bound to the ribosome

Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.

Parkinson's disease (PD) is characterized by the presence of α-synuclein aggregates known as Lewy bodies and Lewy neurites, whose formation is linked to disease development. The causal relation between α-synuclein aggregates and PD is not well understood. We generated a new transgenic mouse line (MI2) expressing human, aggregation-prone truncated 1-120 α-synuclein under the control of the tyrosine hydroxylase promoter. MI2 mice exhibit progressive aggregation of α-synuclein in dopaminergic neurons of the substantia nigra pars compacta and their striatal terminals. This is associated with a progressive reduction of striatal dopamine release, reduced striatal innervation and significant nigral dopaminergic nerve cell death starting from 6 and 12 months of age, respectively. In the MI2 mice, alterations in gait impairment can be detected by the DigiGait test from 9 months of age, while gross motor deficit was detected by rotarod test at 20 months of age when 50% of dopaminergic neurons in the substantia nigra pars compacta are lost. These changes were associated with an increase in the number and density of 20-500 nm α-synuclein species as shown by dSTORM. Treatment with the oligomer modulator anle138b, from 9 to 12 months of age, restored striatal dopamine release, prevented dopaminergic cell death and gait impairment. These effects were associated with a reduction of the inner density of large α-synuclein aggregates and an increase in dispersed small α-synuclein species as revealed by dSTORM. The MI2 mouse model recapitulates the progressive dopaminergic deficit observed in PD, showing that early synaptic dysfunction is associated to fine behavioral motor alterations, precedes dopaminergic axonal loss and neuronal death that become associated with a more consistent motor deficit upon reaching a certain threshold. Our data also provide new mechanistic insight for the effect of anle138b's function in vivo supporting that targeting α-synuclein aggregation is a promising therapeutic approach for PD

Cys-Ph-TAHA: a lanthanide binding tag for RDC and PCS enhanced protein NMR

Here we present Cys-Ph-TAHA, a new nonadentate lanthanide tag for the paramagnetic labelling of proteins. The tag can be easily synthesized and is stereochemically homogenous over a wide range of temperatures, yielding NMR spectra with a single set of peaks. Bound to ubiquitin, it induced large residual dipolar couplings and pseudocontact shifts that could be measured easily and agreed very well with the protein structure. We show that Cys-Ph-TAHA can be used to label large proteins that are biochemically challenging such as the Lac repressor in a 90 kDa ternary complex with DNA and inducer

Reactive SPS of Al2O3–RE:YAG (RE = Ce; Ce+Gd) composite ceramic phosphors

Ultrafine-grained Al2O3–rare earth:yttrium aluminium garnet (Al2O3–RE:YAG) (RE = Ce; Ce+Gd) composite ceramics were obtained for the first time by reactive spark plasma sintering (SPS) using commercially available initial oxide powders. The effect of key sintering parameters (temperature, dwell time, and external pressure (Pload)) on densification peculiarities, structural-phase states, and luminescent properties of composites was studied comprehensively. Differences in phase formation and densification between Ce-doped and Ce,Gd-codoped systems were shown. Parameters of reactive SPS, at which there is partial melting with the formation of near-eutectic zones of the Al2O3–YAG system/coexistence of several variations of the YAG-type phase, were established. Pure corundum–garnet biphasic ceramics with an optimal balance between microstructural and luminescence performance were synthesized at 1425 ℃/30 min/30–60 MPa. The external quantum efficiency (EQE) of the phosphor converters reached 80.7% and 72% with close lifetime of ~63.8 ns, similar to those of commercial Ce:YAG materials, which is promising for further applications in the field of high-power white light-emitting diodes (WLEDs) and laser diodes (LDs)

Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy

BACKGROUND: MSA is a fatal neurodegenerative disease characterized by autonomic failure and severe motor impairment. Its main pathological hallmark is the accumulation of alpha-synuclein in oligodendrocytes, leading to glial and neuronal dysfunction and neurodegeneration. These features are recapitulated in the PLP-halphaSyn mouse model expressing human alpha-synuclein in oligodendrocytes. At present, there is no effective disease-modifying therapy. Previous experiments have shown that the aggregation inhibitor, anle138b, reduces neurodegeneration and behavioral deficits in mouse models of other proteinopathies. OBJECTIVES: To test the therapeutic potential of anle138b in a mouse model of MSA. METHODS: Two-month-old PLP-halphaSyn mice were fed over a period of 4 months with pellets containing anle138b at two different doses (0.6 and 2 g/kg) and compared to healthy controls and PLP-halphaSyn mice fed with placebo pellets. At the end of the treatment, behavioral and histological analyses were performed. RESULTS: We observed a reversal of motor function to healthy control levels when PLP-halphaSyn mice were treated with both doses of anle138b. Histological and molecular analyses showed a significant reduction in alpha-synuclein oligomers and glial cytoplasmic inclusions in animals fed with anle138b compared to nontreated mice. These animals also present preservation of dopaminergic neurons and reduction in microglial activation in SN correlating with the alpha-synuclein reduction observed. CONCLUSIONS: Anle138b reduces alpha-synuclein accumulation in PLP-halphaSyn mice, leading to neuroprotection, reduction of microglial activation, and preservation of motor function supporting the use of anle138b in a future clinical trial for MSA. (c) 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society